Nexalin Technology Inc. (NXL)
NASDAQ: NXL
· Real-Time Price · USD
1.21
-0.02 (-1.63%)
At close: May 27, 2025, 3:59 PM
-1.63% (1D)
| Bid | 1.21 |
| Market Cap | 20.79M |
| Revenue (ttm) | 131.06K |
| Net Income (ttm) | -8.55M |
| EPS (ttm) | -0.84 |
| PE Ratio (ttm) | -1.44 |
| Forward PE | -2.56 |
| Analyst | Buy |
| Ask | 1.25 |
| Volume | 35,070 |
| Avg. Volume (20D) | 118,131 |
| Open | 1.22 |
| Previous Close | 1.23 |
| Day's Range | 1.20 - 1.23 |
| 52-Week Range | 0.53 - 4.49 |
| Beta | 4.73 |
Analyst Forecast
According to 0 analyst ratings, the average rating for NXL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
-25.7%
Nexalin Technology shares are trading lower after ...
Unlock content with
Pro Subscription
6 months ago
+26.91%
Nexalin Technology shares are trading higher after the company announced it regained listing requirements compliance with Nasdaq.
1 year ago · proactiveinvestors.com
Nexalin Technology's neurostimulation device shows promise in easing mTBI symptoms in veteransNexalin Technology has unveiled positive results from a clinical study evaluating its Gen-2 tACS 15 milliamp neurostimulation device to reduce pain in veteran patients with mild Traumatic Brain Injury...
